

June 2, 2023

BSE Limited Code: 532321

P J Towers, Dalal Street, <u>Mumbai-400001</u>

National Stock Exchange of India Limited

Exchange Plaza, C/1, Block G, Bandra-Kurla Complex, Bandra (East), Mumbai-400051

Re.: Notification

Dear Sir / Madam,

Please find attached notification with title "USFDA inspection at Zydus' animal health drug manufacturing facility at SEZ, Ahmedabad".

Code: Zyduslife

Thanking you,

Yours faithfully, For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above

USFDA inspection at Zydus' animal health drug manufacturing facility at SEZ, Ahmedabad

• The inspection concluded with nil observations.

Ahmedabad, India, June 2, 2023

Zydus Lifesciences Ltd., today announced that the group's animal health drug manufacturing facility at SEZ, Ahmedabad underwent a USFDA inspection from 30th May to 2nd June, 2023. The inspection closed with nil observations.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

About Zydus

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 24000 people worldwide and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. For more details visit www.zyduslife.com.